AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02024464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract removal and intraocular lens (IOL) implantation
Description: Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
Study NCT00964418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
Study NCT00964418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: 0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
Study NCT03235908 — intervention group
Intervention type: OTHER
Intervention: Observation only
Description: Observation only
Study NCT01134510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
Study NCT01134510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NS (comparable volume as intervention) twice weekly x 4wks
Study NCT04403438 — intervention group
Intervention type: OTHER
Intervention: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
Description: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
Study NCT04634123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpotomy therapy by White Portland Cement
Description: Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
Study NCT04634123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulpotomy therapy by White MTA
Description: Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
Study NCT03751202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg
Description: 2 inhalations of Test and Reference product in each study period
Study NCT03751202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS
Description: 2 inhalations of Test and Reference product in each study period
Study NCT00629824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
Study NCT00629824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha and plus ribavirin
Description: pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
Study NCT01565486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonic coagulation device (Harmonic ACE® scalpel)
Description: Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
Study NCT01565486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: bipolar energy sealing system (LigaSure Precise)
Description: Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
Study NCT01111370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DexCom™ G4 Continuous Glucose Monitoring System
Description: Continuous Glucose Monitoring System
Study NCT00177489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent psychosocial intervention
Description: The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
Study NCT00177489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention.
Study NCT03448835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab 1200 mg 5 cycles
Study NCT03448835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 850 mg /m2 4 cycles
Study NCT03448835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 100 mg/m2 4 cycles
Study NCT03448835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 50 mg/m2 4 cycles
Study NCT03995771 — intervention group
Intervention type: OTHER
Intervention: Questionnaire delivery
Description: A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
Study NCT03040050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rPCR results
Description: Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
Study NCT03040050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
Study NCT00666185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT00666185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: IV
Study NCT03227926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
Description: Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
Study NCT03227926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular Screening
Description: Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
Study NCT02261740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice.
Study NCT03168061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC 6300
Description: Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
Study NCT04204681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
Study NCT03237208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
Study NCT03237208 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo group
Description: Transcutaneous electrical nerve stimulation treatment will not be activated.
Study NCT00645242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
Study NCT01513018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high tidal volumes
Description: One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used.
Study NCT01513018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low tidal volume
Description: One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used.
Study NCT01042301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samplings
Study NCT01042301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samplings
Study NCT03767738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Description: IAI prepared and administered with a pre-filled syringe (PFS)
Study NCT03887572 — intervention group
Intervention type: OTHER
Intervention: MOVIN
Description: MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
Study NCT02057835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 low dose 1
Description: BI 691751 low dose 1
Study NCT00103727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Comparator
Study NCT00103727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Active Comparator
Study NCT01767831 — intervention group
Intervention type: BEHAVIORAL
Intervention: iBOLUSED
Description: The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
Study NCT02875574 — intervention group
Intervention type: DRUG
Intervention: Any treatment regimen
Description: Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
Study NCT02875574 — intervention group
Intervention type: OTHER
Intervention: Bacterial mutation
Description: Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
Study NCT04668378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
Study NCT04668378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
Study NCT01183858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib [Tarceva]
Description: Single daily oral dose
Study NCT03127020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR309
Description: taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
Study NCT02417415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive heat stress
Description: Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.
Study NCT02417415 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (non-heating)
Description: Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
Study NCT02975323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
Study NCT06074172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol in Oral Dose Form
Description: Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
Study NCT06074172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in Oral Dose Form
Description: Placebo press pills provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
Study NCT01047787 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: examination for sleep disorders
Study NCT01386671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin glycinate
Description: Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
Study NCT01386671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride
Description: 12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
Study NCT02437669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: To be administered by intranasal route using mucosal atomization device.
Study NCT05736315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo dairy beverage
Description: Placebo dairy beverage (placebo) is a sweetened dairy beverage.
Study NCT05736315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dairy beverage
Description: Placebo dairy beverage (placebo) is a sweetened dairy beverage.
Study NCT04754373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GFA-918
Description: Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
Study NCT04754373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
Study NCT01570010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Norwegian food based dietary guidelines
Description: several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
Study NCT01570010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norwegian food based dietary guidelines
Description: several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
Study NCT02797561 — intervention group
Intervention type: OTHER
Intervention: 5 year Follow-up
Study NCT02088034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotora-led Intervention
Description: Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
Study NCT02088034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Therapy
Description: Participants in this group will receive metformin 850 mg bid for one year.
Study NCT02088034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
Study NCT00661765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline tartrate
Description: Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
Study NCT00661765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline free base
Description: A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
Study NCT00792766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus (RAD001)
Description: Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
Study NCT00768378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with the BrainPort balance device
Description: Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
Study NCT01720771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic tablet
Description: Intake of one probiotic lozenge tablet per day
Study NCT01720771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: one tablet daily
Study NCT02704429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRN1008
Description: Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks.
Study NCT04283877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 3 x 10 mg oral tablets. Single acute dose for all participants
Study NCT04283877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 3 x 10 mg oral lactose tablet for all participants
Study NCT01380093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
Study NCT01380093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS Contin (morphine sulfate, controlled release)
Description: Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
Study NCT01380093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMBEDA (morphine sulfate / naltrexone hydrochloride)
Description: Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
Study NCT00091793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162
Description: 60 mg/mL denosumab given day 1, month 6, month 12 and month 18
Study NCT00091793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at day 1, month 6, month 12 and month 18